These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
342 related articles for article (PubMed ID: 25920038)
1. The Relationship between Acute Dyskinesia with a Single Dose of Methylphenidate and Recent Risperidone Discontinuation in a Child with Attention-Deficit/Hyperactivity Disorder. Ince E; Algedik P; Demirdogen ES; Emul M; Demir T J Child Adolesc Psychopharmacol; 2015 May; 25(4):378-9. PubMed ID: 25920038 [No Abstract] [Full Text] [Related]
2. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. Aman MG; Binder C; Turgay A J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021 [TBL] [Abstract][Full Text] [Related]
4. Risperidone-to-methylphenidate switch reaction in children: three cases. Sabuncuoglu O J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303 [TBL] [Abstract][Full Text] [Related]
5. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. Masi G; Manfredi A; Nieri G; Muratori P; Pfanner C; Milone A J Clin Psychopharmacol; 2017 Oct; 37(5):590-594. PubMed ID: 28806385 [TBL] [Abstract][Full Text] [Related]
6. The influence of risperidone on attentional functions in children and adolescents with attention-deficit/hyperactivity disorder and co-morbid disruptive behavior disorder. Günther T; Herpertz-Dahlmann B; Jolles J; Konrad K J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):725-35. PubMed ID: 17201616 [TBL] [Abstract][Full Text] [Related]
7. Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder. Pae CU Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1149-50; author reply 1151-2. PubMed ID: 17493730 [No Abstract] [Full Text] [Related]
8. Understanding Chronic Aggression and Its Treatment in Children and Adolescents. Magalotti SR; Neudecker M; Zaraa SG; McVoy MK Curr Psychiatry Rep; 2019 Nov; 21(12):123. PubMed ID: 31741142 [TBL] [Abstract][Full Text] [Related]
9. Medications used in the treatment of disruptive behavior in children with FASD--a guide. Ozsarfati J; Koren G J Popul Ther Clin Pharmacol; 2015; 22(1):e59-67. PubMed ID: 25715382 [TBL] [Abstract][Full Text] [Related]
10. Methylphenidate an effective treatment for ADHD? McDougle CJ J Autism Dev Disord; 2004 Oct; 34(5):593-4. PubMed ID: 15628613 [No Abstract] [Full Text] [Related]
11. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. Farmer CA; Brown NV; Gadow KD; Arnold LE; Kolko DG; Findling RL; Molina BS; Buchan-Page KA; Rice RR; Bangalore SS; Bukstein O; Rundberg-Rivera EV; McNamara N; Aman MG J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):213-24. PubMed ID: 25885011 [TBL] [Abstract][Full Text] [Related]
12. Pemoline in ADHD. Winsberg B; Barbato M J Am Acad Child Adolesc Psychiatry; 1997 Dec; 36(12):1649-50. PubMed ID: 9401321 [No Abstract] [Full Text] [Related]
13. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. Arnold LE; Gadow KD; Farmer CA; Findling RL; Bukstein O; Molina BS; Brown NV; Li X; Rundberg-Rivera EV; Bangalore S; Buchan-Page K; Hurt EA; Rice R; McNamara NK; Aman MG J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):203-12. PubMed ID: 25885010 [TBL] [Abstract][Full Text] [Related]
14. Acute dyskinesia on starting methylphenidate after risperidone withdrawal. Hollis CP; Thompson A Pediatr Neurol; 2007 Oct; 37(4):287-8. PubMed ID: 17903675 [TBL] [Abstract][Full Text] [Related]
15. A symposium on Attention Deficit Hyperactivity Disorder (ADHD). Developments in treatment. Levy F Aust N Z J Psychiatry; 2002 Aug; 36(4):477-9. PubMed ID: 12169142 [No Abstract] [Full Text] [Related]
16. Not just another antipsychotic-for-conduct-problems trial. Blader JC J Am Acad Child Adolesc Psychiatry; 2014 Jan; 53(1):17-20. PubMed ID: 24342382 [No Abstract] [Full Text] [Related]
17. Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression. Joseph HM; Farmer C; Kipp H; Kolko D; Aman M; McGinley J; Arnold LE; Gadow KD; Findling RL; Molina BSG J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):90-99. PubMed ID: 30592635 [TBL] [Abstract][Full Text] [Related]
18. Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. Armenteros JL; Lewis JE; Davalos M J Am Acad Child Adolesc Psychiatry; 2007 May; 46(5):558-565. PubMed ID: 17450046 [TBL] [Abstract][Full Text] [Related]
19. Stimulant adherence and academic performance in urban youth with attention-deficit/hyperactivity disorder. Marcus SC; Durkin M J Am Acad Child Adolesc Psychiatry; 2011 May; 50(5):480-9. PubMed ID: 21515197 [TBL] [Abstract][Full Text] [Related]
20. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. Rundberg-Rivera EV; Townsend LD; Schneider J; Farmer CA; Molina BB; Findling RL; Gadow KD; Bukstein OG; Arnold LE; Kolko DJ; Buchan-Page KA; McNamara NK; Michel C; Austin A; Kipp H; Rice RR; Aman MG J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):225-33. PubMed ID: 25885012 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]